首页 > 最新文献

Human Mutation最新文献

英文 中文
Stem Cell–Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy 干细胞相关基因CALR作为膀胱癌新的预后因子:免疫治疗的意义。
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-12-17 DOI: 10.1155/humu/5569005
Zhihao Ling, Shuo He, Tianyu Li, Jiandong Zhang, Beibei Liu

Cancer stem cells (CSCs) are a unique category of cells located within tumors, characterized by their exceptional self-renewal abilities and capacity to differentiate into different types of tumor cells. These cells are crucial in processes such as tumor metastasis, recurrence, and resistance to treatment. Nevertheless, their particular roles in bladder urothelial carcinoma (BLCA) require deeper exploration. This investigation firstly assessed the relationships between genes associated with CSCs and both the prognostic outcomes and responses to immunotherapy in patients with BLCA using cluster analysis methods. Among the genes linked to stem cells, CALR was identified as the most notable prognostic marker by the XGBoost algorithm. Additionally, the study explored the correlation between CALR and immune cell infiltration, as well as its interaction with mitomycin using molecular docking methods. In vitro experiments further validated that CALR affects BLCA stem cells. Utilizing multiple machine learning approaches, this study identified 14 essential stem cell–associated genes, underscoring their significance for BLCA diagnosis and potential therapeutic targeting. Critically, CALR demonstrates a strong correlation with prognostic outcomes and immunotherapy responses in BLCA, consistent with experimental findings indicating its elevated expression in BLCA and association with poor prognosis. Laboratory investigations have demonstrated that reducing CALR expression can lessen the stemness features of BLCA. Our results highlight the critical role of genes related to stem cells in BLCA and identify CALR as a promising target associated with stem cell functionality.

肿瘤干细胞(Cancer stem cells, CSCs)是肿瘤中一类独特的细胞,其特点是具有卓越的自我更新能力和分化成不同类型肿瘤细胞的能力。这些细胞在肿瘤转移、复发和治疗抵抗等过程中起着至关重要的作用。然而,它们在膀胱尿路上皮癌(BLCA)中的特殊作用需要更深入的探讨。本研究首先使用聚类分析方法评估了与CSCs相关的基因与BLCA患者的预后和免疫治疗反应之间的关系。在与干细胞相关的基因中,通过XGBoost算法,CALR被确定为最显著的预后标志物。此外,本研究还利用分子对接方法探讨了CALR与免疫细胞浸润的关系,以及CALR与丝裂霉素的相互作用。体外实验进一步验证了CALR对BLCA干细胞的影响。利用多种机器学习方法,本研究确定了14个必要的干细胞相关基因,强调了它们对BLCA诊断和潜在治疗靶向的重要性。重要的是,CALR与BLCA的预后结果和免疫治疗反应密切相关,这与实验结果一致,表明CALR在BLCA中的表达升高并与不良预后相关。实验室研究表明,减少CALR表达可以减轻BLCA的干性特征。我们的研究结果强调了与干细胞相关的基因在BLCA中的关键作用,并确定CALR是与干细胞功能相关的有希望的靶标。
{"title":"Stem Cell–Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy","authors":"Zhihao Ling,&nbsp;Shuo He,&nbsp;Tianyu Li,&nbsp;Jiandong Zhang,&nbsp;Beibei Liu","doi":"10.1155/humu/5569005","DOIUrl":"10.1155/humu/5569005","url":null,"abstract":"<p>Cancer stem cells (CSCs) are a unique category of cells located within tumors, characterized by their exceptional self-renewal abilities and capacity to differentiate into different types of tumor cells. These cells are crucial in processes such as tumor metastasis, recurrence, and resistance to treatment. Nevertheless, their particular roles in bladder urothelial carcinoma (BLCA) require deeper exploration. This investigation firstly assessed the relationships between genes associated with CSCs and both the prognostic outcomes and responses to immunotherapy in patients with BLCA using cluster analysis methods. Among the genes linked to stem cells, CALR was identified as the most notable prognostic marker by the XGBoost algorithm. Additionally, the study explored the correlation between CALR and immune cell infiltration, as well as its interaction with mitomycin using molecular docking methods. In vitro experiments further validated that CALR affects BLCA stem cells. Utilizing multiple machine learning approaches, this study identified 14 essential stem cell–associated genes, underscoring their significance for BLCA diagnosis and potential therapeutic targeting. Critically, CALR demonstrates a strong correlation with prognostic outcomes and immunotherapy responses in BLCA, consistent with experimental findings indicating its elevated expression in BLCA and association with poor prognosis. Laboratory investigations have demonstrated that reducing CALR expression can lessen the stemness features of BLCA. Our results highlight the critical role of genes related to stem cells in BLCA and identify CALR as a promising target associated with stem cell functionality.</p>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12714107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Likely Pathogenic/Pathogenic Variants in the Spliceosome Complex Genes SNRNP200, SF3B1, SF3B2, and SF3B4 Implicated in Nonsyndromic Orofacial Cleft 剪接体复合体基因SNRNP200、SF3B1、SF3B2和SF3B4可能与非综合征性口面部裂有关。
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-12-14 DOI: 10.1155/humu/2991452
Peyman Ranji, Eleonore Pairet, Raphael Helaers, Pascal Brouillard, Bénédicte Bayet, Alexander Gerdom, Nicole Revencu, Miikka Vikkula

The genetic basis of nonsyndromic orofacial cleft (NsOFC) remains elusive, although associations have been identified with various genetic loci. NsOFC has a less pronounced genetic background than syndromic orofacial cleft (SyOFC), albeit Mendelian inheritance has been identified. Our hypothesis was that genes related to spliceosome function may contribute to NsOFC pathophysiology, as they do for some syndromic cases. Exome sequencing was conducted on 224 unrelated NsOFC probands. We performed filtering and analyses of predicted pathogenicity of rare variants using Highlander. We focused on 26 genes encoding spliceosome proteins. Subsequently, bioinformatic tools, such as AlphaFold, and PyMol, were applied to generate three-dimensional structures to interpret the effects of the identified variants on protein structure and interaction domains. We found six likely damaging variants: three heterozygous missense variants in small nuclear ribonucleoprotein U5 200 kDa subunit (SNRNP200) in three multiplex NsOFC families, and two missense and one splice site variant in splicing factor 3b subunit 1 (SF3B1), 4 (SF3B4), and 2 (SF3B2) in two posterior CP families and a complete CP patient, respectively. These results suggest that variants in the spliceosome complex genes, observed in 2.7% of NsOFC cases in our cohort, may contribute to disease susceptibility as potential risk factors.

非综合征性口面裂(NsOFC)的遗传基础仍然难以捉摸,尽管已经确定了与各种遗传位点的关联。尽管孟德尔遗传已被确定,但NsOFC的遗传背景不如综合征性口面裂(SyOFC)明显。我们的假设是,与剪接体功能相关的基因可能与NsOFC的病理生理有关,就像它们在一些综合征病例中所做的那样。对224个不相关的NsOFC先证子进行外显子组测序。我们使用汉兰达对罕见变异的预测致病性进行筛选和分析。我们重点研究了26个编码剪接体蛋白的基因。随后,生物信息学工具(如AlphaFold和PyMol)被应用于生成三维结构,以解释鉴定的变异对蛋白质结构和相互作用域的影响。我们发现了六种可能的破坏性变异:在三个多重型NsOFC家族中,小核核糖核蛋白U5 200 kDa亚基(SNRNP200)中有三个杂合错义变异,在两个后CP家族和一个完全CP患者中,分别在剪接因子3b亚基1 (SF3B1)、4 (SF3B4)和2 (SF3B2)中有两个错义和一个剪接位点变异。这些结果表明,在我们的队列中2.7%的NsOFC病例中观察到的剪接体复合体基因变异可能作为潜在的危险因素导致疾病易感性。
{"title":"Likely Pathogenic/Pathogenic Variants in the Spliceosome Complex Genes SNRNP200, SF3B1, SF3B2, and SF3B4 Implicated in Nonsyndromic Orofacial Cleft","authors":"Peyman Ranji,&nbsp;Eleonore Pairet,&nbsp;Raphael Helaers,&nbsp;Pascal Brouillard,&nbsp;Bénédicte Bayet,&nbsp;Alexander Gerdom,&nbsp;Nicole Revencu,&nbsp;Miikka Vikkula","doi":"10.1155/humu/2991452","DOIUrl":"10.1155/humu/2991452","url":null,"abstract":"<p>The genetic basis of nonsyndromic orofacial cleft (NsOFC) remains elusive, although associations have been identified with various genetic loci. NsOFC has a less pronounced genetic background than syndromic orofacial cleft (SyOFC), albeit Mendelian inheritance has been identified. Our hypothesis was that genes related to spliceosome function may contribute to NsOFC pathophysiology, as they do for some syndromic cases. Exome sequencing was conducted on 224 unrelated NsOFC probands. We performed filtering and analyses of predicted pathogenicity of rare variants using Highlander. We focused on 26 genes encoding spliceosome proteins. Subsequently, bioinformatic tools, such as AlphaFold, and PyMol, were applied to generate three-dimensional structures to interpret the effects of the identified variants on protein structure and interaction domains. We found six likely damaging variants: three heterozygous missense variants in small nuclear ribonucleoprotein U5 200 kDa subunit (<i>SNRNP200</i>) in three multiplex NsOFC families, and two missense and one splice site variant in splicing factor 3b subunit 1 (<i>SF3B1</i>), 4 (<i>SF3B4</i>), and 2 (<i>SF3B2</i>) in two posterior CP families and a complete CP patient, respectively. These results suggest that variants in the spliceosome complex genes, observed in 2.7% of NsOFC cases in our cohort, may contribute to disease susceptibility as potential risk factors.</p>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12714162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated Multiomics Unravels Hedgehog (HH) Signaling Characteristics in Pancreatic Cancer (PC) and DCBLD2 Regulates HH Signaling to Drive PC Progression 整合多组学揭示胰腺癌(PC)中的Hedgehog (HH)信号特征,dbld2调节HH信号驱动PC进展
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-12-11 DOI: 10.1155/humu/4806397
Biao Zhang, Bingqian Huang, Xinya Zhao, Bolin Zhang, Jinming Liu, Chongchan Bao, Zhizhou Wang

Hedgehog (HH) signaling plays a crucial role in cancer development. However, HH signaling–related molecular characteristics have not been comprehensively evaluated in pancreatic cancer (PC). This study dissected the characteristics of HH signaling in PC using integrated bulk and single-cell profiling. GSEA indicated that HH signaling is significantly enriched in PC tissue. Consensus clustering was utilized to classify PC samples into two HH signaling–related subtypes: HRGcluster A and HRGcluster B. In contrast with HRGcluster A, HRGcluster B has an earlier clinical stage, better outcome, less active level of HH signaling, higher infiltration level of CD8+ T cells and B cells, and a greater likelihood of benefiting from immunotherapy and gemcitabine chemotherapy. Moreover, an HH signaling–related prognostic model (including ANLN, SERPINB3, LY6D, and DCBLD2) with excellent prediction performance was established and validated. Further analysis indicated that ANLN, SERPINB3, LY6D, and DCBLD2 were significantly upregulated in PC and associated with poor prognosis. Single-cell analysis revealed that HH signaling is relatively more active in PC cells, and PC cells with DCBLD2 high expression had significantly higher HH signaling scores. In vitro assays further indicated that DCBLD2 knockdown downregulates HH signaling and inhibits the proliferation, migration, and invasion of PC cells. In conclusion, this study reveals that HH signaling characteristics in PC and DCBLD2 regulate HH signaling to drive PC progression, providing new perspectives and theories for the diagnosis and treatment of PC.

Hedgehog (HH)信号在癌症发展中起着至关重要的作用。然而,胰腺癌(PC)中HH信号相关的分子特征尚未得到全面评估。本研究通过整体和单细胞分析分析了PC中HH信号的特征。GSEA显示,PC组织中HH信号显著富集。采用共识聚类法将PC样本分为HRGcluster A和HRGcluster B两种HH信号相关亚型。与HRGcluster A相比,HRGcluster B临床分期更早,预后更好,HH信号活性水平更低,CD8+ T细胞和B细胞浸润水平更高,更有可能从免疫治疗和吉西他滨化疗中获益。建立并验证了具有良好预测性能的HH信号相关预后模型(包括ANLN、SERPINB3、LY6D和DCBLD2)。进一步分析表明,ANLN、SERPINB3、LY6D和DCBLD2在PC中显著上调,并与不良预后相关。单细胞分析显示,HH信号在PC细胞中相对更活跃,DCBLD2高表达的PC细胞HH信号评分明显更高。体外实验进一步表明,dbld2敲低可下调HH信号,抑制PC细胞的增殖、迁移和侵袭。总之,本研究揭示了PC中的HH信号特征和DCBLD2调控HH信号驱动PC进展,为PC的诊断和治疗提供了新的视角和理论。
{"title":"Integrated Multiomics Unravels Hedgehog (HH) Signaling Characteristics in Pancreatic Cancer (PC) and DCBLD2 Regulates HH Signaling to Drive PC Progression","authors":"Biao Zhang,&nbsp;Bingqian Huang,&nbsp;Xinya Zhao,&nbsp;Bolin Zhang,&nbsp;Jinming Liu,&nbsp;Chongchan Bao,&nbsp;Zhizhou Wang","doi":"10.1155/humu/4806397","DOIUrl":"https://doi.org/10.1155/humu/4806397","url":null,"abstract":"<p>Hedgehog (HH) signaling plays a crucial role in cancer development. However, HH signaling–related molecular characteristics have not been comprehensively evaluated in pancreatic cancer (PC). This study dissected the characteristics of HH signaling in PC using integrated bulk and single-cell profiling. GSEA indicated that HH signaling is significantly enriched in PC tissue. Consensus clustering was utilized to classify PC samples into two HH signaling–related subtypes: HRGcluster A and HRGcluster B. In contrast with HRGcluster A, HRGcluster B has an earlier clinical stage, better outcome, less active level of HH signaling, higher infiltration level of CD8+ T cells and B cells, and a greater likelihood of benefiting from immunotherapy and gemcitabine chemotherapy. Moreover, an HH signaling–related prognostic model (including ANLN, SERPINB3, LY6D, and DCBLD2) with excellent prediction performance was established and validated. Further analysis indicated that ANLN, SERPINB3, LY6D, and DCBLD2 were significantly upregulated in PC and associated with poor prognosis. Single-cell analysis revealed that HH signaling is relatively more active in PC cells, and PC cells with DCBLD2 high expression had significantly higher HH signaling scores. In vitro assays further indicated that DCBLD2 knockdown downregulates HH signaling and inhibits the proliferation, migration, and invasion of PC cells. In conclusion, this study reveals that HH signaling characteristics in PC and DCBLD2 regulate HH signaling to drive PC progression, providing new perspectives and theories for the diagnosis and treatment of PC.</p>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/4806397","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic and Immune Adaptations in Preterm Neonates at Early Postnatal Period: Integrated Analysis of Key Metabolites and Pathways 早产儿在产后早期的代谢和免疫适应:关键代谢产物和途径的综合分析
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-12-08 DOI: 10.1155/humu/9978047
Xiaofan Li, Yue Gan, Lan Tan, Yuxi Lin, Pengxi Zhou, Jue Wang, Bing Yang, Quan Tang

Objective

This study was aimed at clarifying the unique metabolic alterations in preterm neonates, distinct from full-term neonates, between the first 24 and 48 h postnatally.

Methods

A cohort of 60 preterm and 60 full-term neonates was analyzed. The metabolomic profiles of plasma samples were determined using ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS). Multivariate statistical analyses were employed to discern metabolic differences. Multiple machine learning models were constructed to further select key metabolites. Spearman′s correlation analysis was performed to assess the correlation between neonatal immune cell subsets and key metabolites.

Results

The study revealed 70 specific metabolic alterations in preterm neonates during the early postnatal period. Then, 32 of these metabolites were jointly selected by the Top 5 machine learning models, which exhibited high predictive performance with an AUC > 0.9. Subsequent analyses including multivariable linear regression and ROC curve revealed 12 key metabolites significantly associated with gestational age. Correlation analyses exposed significant associations between immune cells and these metabolites. Integrated pathway analysis identified 10 key metabolic pathways involved in preterm neonates. NMR-based validation confirmed two of the 12 prioritized metabolites and six additional metabolites from the broader panel, supporting the robustness of our findings.

Conclusion

Our findings provide insights into the metabolic and immune adaptation processes in preterm neonates during the early life stage. The correlations between immune cell subsets and the key metabolites highlight a potential effect of metabolism on immune adaptation in preterm neonates. These key metabolites and pathways could serve as potential biomarkers for early diagnosis and therapeutic strategies to enhance immune function and health outcomes in preterm infants.

目的本研究旨在阐明早产儿(不同于足月新生儿)在出生后24至48小时内独特的代谢变化。方法对60例早产儿和60例足月新生儿进行回顾性分析。采用超高效液相色谱-四极杆飞行时间质谱法(UPLC-QTOF-MS)测定血浆样品的代谢组学特征。采用多变量统计分析来辨别代谢差异。构建了多个机器学习模型来进一步选择关键代谢物。进行Spearman相关分析以评估新生儿免疫细胞亚群与关键代谢物之间的相关性。结果本研究揭示了早产儿在产后早期的70种特异性代谢改变。然后,通过Top 5机器学习模型共同选择其中的32种代谢物,这些模型具有较高的预测性能,AUC > 0.9。随后的多变量线性回归和ROC曲线分析显示12种关键代谢物与胎龄显著相关。相关分析揭示了免疫细胞和这些代谢物之间的显著关联。综合通路分析确定了10个涉及早产儿的关键代谢通路。基于核磁共振的验证证实了12种优先代谢物中的2种和来自更广泛小组的6种额外代谢物,支持了我们研究结果的稳健性。结论本研究为早产儿早期的代谢和免疫适应过程提供了新的思路。免疫细胞亚群与关键代谢物之间的相关性突出了代谢对早产儿免疫适应的潜在影响。这些关键代谢物和途径可以作为早期诊断和治疗策略的潜在生物标志物,以增强早产儿的免疫功能和健康结局。
{"title":"Metabolic and Immune Adaptations in Preterm Neonates at Early Postnatal Period: Integrated Analysis of Key Metabolites and Pathways","authors":"Xiaofan Li,&nbsp;Yue Gan,&nbsp;Lan Tan,&nbsp;Yuxi Lin,&nbsp;Pengxi Zhou,&nbsp;Jue Wang,&nbsp;Bing Yang,&nbsp;Quan Tang","doi":"10.1155/humu/9978047","DOIUrl":"https://doi.org/10.1155/humu/9978047","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study was aimed at clarifying the unique metabolic alterations in preterm neonates, distinct from full-term neonates, between the first 24 and 48 h postnatally.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cohort of 60 preterm and 60 full-term neonates was analyzed. The metabolomic profiles of plasma samples were determined using ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS). Multivariate statistical analyses were employed to discern metabolic differences. Multiple machine learning models were constructed to further select key metabolites. Spearman′s correlation analysis was performed to assess the correlation between neonatal immune cell subsets and key metabolites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study revealed 70 specific metabolic alterations in preterm neonates during the early postnatal period. Then, 32 of these metabolites were jointly selected by the Top 5 machine learning models, which exhibited high predictive performance with an AUC &gt; 0.9. Subsequent analyses including multivariable linear regression and ROC curve revealed 12 key metabolites significantly associated with gestational age. Correlation analyses exposed significant associations between immune cells and these metabolites. Integrated pathway analysis identified 10 key metabolic pathways involved in preterm neonates. NMR-based validation confirmed two of the 12 prioritized metabolites and six additional metabolites from the broader panel, supporting the robustness of our findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings provide insights into the metabolic and immune adaptation processes in preterm neonates during the early life stage. The correlations between immune cell subsets and the key metabolites highlight a potential effect of metabolism on immune adaptation in preterm neonates. These key metabolites and pathways could serve as potential biomarkers for early diagnosis and therapeutic strategies to enhance immune function and health outcomes in preterm infants.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/9978047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Aging-Related Hub Genes (ATP11B, RBBP7, DOCK10, and NUP160) as Potential Biomarkers and Therapeutic Targets in Sepsis 衰老相关中心基因(ATP11B、RBBP7、DOCK10和NUP160)作为败血症潜在生物标志物和治疗靶点的鉴定
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-12-04 DOI: 10.1155/humu/9789556
Xueyi Sun, Shaolei Geng, Zeyuan Wang, Qingjiang Chen

Sepsis arises from a dysregulated host response to infection, leading to multiorgan inflammatory injury. Early diagnosis and treatment necessitate the identification of reliable immune biomarkers. This study investigated the relationship between aging, immunity, and sepsis by analyzing six human aging-related gene sets (656 genes). We identified 16 aging-related differentially expressed genes (DEGs) in sepsis. Among these, ATP11B, RBBP7, DOCK10, and NUP160 demonstrated the strongest connectivity with other genes and exhibited significant predictive power. Functional enrichment analysis (GO and KEGG) revealed distinct signaling pathway profiles between high-risk and low-risk sepsis groups (stratified based on risk scores). These dysregulated pathways, associated with multiple immune cells, were primarily linked to transcriptional dysregulation in cellular processes and cancer-related pathways. Experimental validation assays corroborated the roles of ATP11B and RBBP7. Collectively, our bioinformatic and experimental findings indicate that ATP11B, RBBP7, DOCK10, and NUP160 are implicated in the pathogenesis and progression of sepsis. But their potential for sepsis biomarkers still requires further verification.

脓毒症源于宿主对感染的反应失调,导致多器官炎症损伤。早期诊断和治疗需要确定可靠的免疫生物标志物。本研究通过分析6组人类衰老相关基因(656个基因),探讨了衰老、免疫和败血症之间的关系。我们在脓毒症中发现了16个与衰老相关的差异表达基因(DEGs)。其中,ATP11B、RBBP7、DOCK10和NUP160与其他基因的连通性最强,具有显著的预测能力。功能富集分析(GO和KEGG)揭示了高风险和低风险败血症组之间不同的信号通路特征(根据风险评分分层)。这些与多种免疫细胞相关的失调通路主要与细胞过程和癌症相关通路中的转录失调有关。实验验证分析证实了ATP11B和RBBP7的作用。总之,我们的生物信息学和实验结果表明,ATP11B、RBBP7、DOCK10和NUP160与脓毒症的发病和进展有关。但它们作为败血症生物标志物的潜力仍需要进一步验证。
{"title":"Identification of Aging-Related Hub Genes (ATP11B, RBBP7, DOCK10, and NUP160) as Potential Biomarkers and Therapeutic Targets in Sepsis","authors":"Xueyi Sun,&nbsp;Shaolei Geng,&nbsp;Zeyuan Wang,&nbsp;Qingjiang Chen","doi":"10.1155/humu/9789556","DOIUrl":"https://doi.org/10.1155/humu/9789556","url":null,"abstract":"<p>Sepsis arises from a dysregulated host response to infection, leading to multiorgan inflammatory injury. Early diagnosis and treatment necessitate the identification of reliable immune biomarkers. This study investigated the relationship between aging, immunity, and sepsis by analyzing six human aging-related gene sets (656 genes). We identified 16 aging-related differentially expressed genes (DEGs) in sepsis. Among these, ATP11B, RBBP7, DOCK10, and NUP160 demonstrated the strongest connectivity with other genes and exhibited significant predictive power. Functional enrichment analysis (GO and KEGG) revealed distinct signaling pathway profiles between high-risk and low-risk sepsis groups (stratified based on risk scores). These dysregulated pathways, associated with multiple immune cells, were primarily linked to transcriptional dysregulation in cellular processes and cancer-related pathways. Experimental validation assays corroborated the roles of ATP11B and RBBP7. Collectively, our bioinformatic and experimental findings indicate that ATP11B, RBBP7, DOCK10, and NUP160 are implicated in the pathogenesis and progression of sepsis. But their potential for sepsis biomarkers still requires further verification.</p>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/9789556","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative Transcriptomic and Machine Learning Analysis Identifies Key Senescence-Associated Secretory Phenotype Genes Associated With Immune Dysregulation in Periodontitis 综合转录组学和机器学习分析识别与牙周炎免疫失调相关的关键衰老相关分泌表型基因
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-12-02 DOI: 10.1155/humu/3637248
Jing Zeng, Jing Huang, Juan He, Jianqin Tan, Mianmian Duan, Yanyan Song, Lin Yang

Periodontitis (PD) is a chronic inflammatory disorder marked by immune dysregulation and progressive tissue destruction. Cellular senescence and the senescence-associated secretory phenotype (SASP) have been increasingly recognized as pivotal drivers of chronic inflammation. However, their specific contributions to PD remain insufficiently clarified. In this study, integrative bioinformatic analyses were conducted across transcriptomic datasets, employing least absolute shrinkage and selection operator, support vector machine–recursive feature elimination, and eXtreme gradient boosting algorithms to identify SASP-related genes of significance. ICAM1, CXCL12, and MMP3 were found to be markedly upregulated in PD and demonstrated strong diagnostic potential through receiver operating characteristic and artificial neural network models. Functional enrichment analysis indicated their involvement in immune cell adhesion, migration, and infection-associated pathways. Immune infiltration profiling revealed disrupted immune landscapes, with ICAM1 exhibiting a negative correlation with resting mast cells. Experimental validation using real-time quantitative polymerase chain reaction and immunohistochemistry on clinical samples confirmed elevated expression of these genes at both the mRNA and protein levels. Moreover, dexamethasone was identified via molecular docking as a potential therapeutic compound targeting ICAM1 and CXCL12. Collectively, these findings advance the understanding of SASP associated with immune regulation in PD and suggest potential biomarkers and therapeutic targets for early diagnosis and intervention.

牙周炎(PD)是一种以免疫失调和进行性组织破坏为特征的慢性炎症性疾病。细胞衰老和衰老相关分泌表型(SASP)越来越被认为是慢性炎症的关键驱动因素。然而,他们对帕金森病的具体贡献仍然不够明确。在本研究中,对转录组数据集进行了综合生物信息学分析,采用最小绝对收缩和选择算子、支持向量机递归特征消除和极端梯度增强算法来识别sasp相关的重要基因。通过受体操作特征和人工神经网络模型,发现ICAM1、CXCL12和MMP3在PD中显著上调,具有很强的诊断潜力。功能富集分析表明它们参与免疫细胞粘附、迁移和感染相关途径。免疫浸润谱显示免疫景观被破坏,ICAM1与静止肥大细胞呈负相关。利用实时定量聚合酶链反应和免疫组织化学对临床样本进行的实验验证证实,这些基因在mRNA和蛋白水平上的表达均有所升高。此外,通过分子对接,地塞米松被鉴定为靶向ICAM1和CXCL12的潜在治疗化合物。总的来说,这些发现促进了对帕金森病中SASP与免疫调节相关的理解,并为早期诊断和干预提供了潜在的生物标志物和治疗靶点。
{"title":"Integrative Transcriptomic and Machine Learning Analysis Identifies Key Senescence-Associated Secretory Phenotype Genes Associated With Immune Dysregulation in Periodontitis","authors":"Jing Zeng,&nbsp;Jing Huang,&nbsp;Juan He,&nbsp;Jianqin Tan,&nbsp;Mianmian Duan,&nbsp;Yanyan Song,&nbsp;Lin Yang","doi":"10.1155/humu/3637248","DOIUrl":"https://doi.org/10.1155/humu/3637248","url":null,"abstract":"<p>Periodontitis (PD) is a chronic inflammatory disorder marked by immune dysregulation and progressive tissue destruction. Cellular senescence and the senescence-associated secretory phenotype (SASP) have been increasingly recognized as pivotal drivers of chronic inflammation. However, their specific contributions to PD remain insufficiently clarified. In this study, integrative bioinformatic analyses were conducted across transcriptomic datasets, employing least absolute shrinkage and selection operator, support vector machine–recursive feature elimination, and eXtreme gradient boosting algorithms to identify SASP-related genes of significance. ICAM1, CXCL12, and MMP3 were found to be markedly upregulated in PD and demonstrated strong diagnostic potential through receiver operating characteristic and artificial neural network models. Functional enrichment analysis indicated their involvement in immune cell adhesion, migration, and infection-associated pathways. Immune infiltration profiling revealed disrupted immune landscapes, with ICAM1 exhibiting a negative correlation with resting mast cells. Experimental validation using real-time quantitative polymerase chain reaction and immunohistochemistry on clinical samples confirmed elevated expression of these genes at both the mRNA and protein levels. Moreover, dexamethasone was identified via molecular docking as a potential therapeutic compound targeting ICAM1 and CXCL12. Collectively, these findings advance the understanding of SASP associated with immune regulation in PD and suggest potential biomarkers and therapeutic targets for early diagnosis and intervention.</p>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/3637248","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whole Genome Sequencing Improves the Identification of Pathogenic and Novel Variation in Nonsyndromic Hearing Loss 全基因组测序提高了对非综合征性听力损失致病性和新变异的识别
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-12-01 DOI: 10.1155/humu/6371082
Stefan Rentas, Ramakrishnan Rajagopalan, Tolga Ayazseven, Mahdi Sarmady, Sarah E. Raible, Ian D. Krantz, Ahmad N. Abou Tayoun

Background

Genetic testing is essential to the diagnosis of nonsyndromic bilateral sensorineural hearing loss (BSNHL), where pathogenic variants in GJB2 are the most common cause. Current testing strategies often fail to provide a comprehensive diagnosis and typically require the use of multiple testing methodologies. This study evaluated the diagnostic utility of genome sequencing (GS) in a cohort with heterozygosity for GJB2 pathogenic variants and BSNHL.

Methods

A retrospective cohort of 23 individuals with BSNHL and a heterozygous pathogenic variant in GJB2 underwent targeted GJB2 resequencing and variant reinterpretation. Those without biallelic GJB2 variants upon single gene reanalysis proceeded to exome sequencing (ES) using a large virtual panel of hearing loss–associated genes. Subjects with no definitive diagnosis from ES subsequently underwent GS. Variants were interpreted using hearing loss–specific ACMG guidelines and published literature.

Results

Three individuals were diagnosed with biallelic pathogenic variants upon GJB2 single gene reanalysis. ES identified a definitive or likely diagnosis in five different hearing loss–related genes in 5/20 (25%) individuals, while two additional cases remained inconclusive due to novel or ambiguous variants in two other hearing loss–associated genes. GS of the remaining 15 cases yielded diagnoses in three individuals, including the identification of deletions in LOXHD1 and STRC, and a recently characterized 125 kb deletion overlapping CRYL1, which refines a critical upstream regulatory region associated with GJB2-related hearing loss. Overall, 11/23 (48%) individuals received a diagnosis with our stepwise testing approach, with GS providing sequencing coverage of all findings.

Conclusion

GS improves diagnostic yield in patients with BSNHL, capturing both SNVs and CNVs missed by ES and targeted testing, and supports its adoption as a comprehensive first-tier diagnostic test for nonsyndromic hearing loss.

基因检测对于非综合征性双侧感音神经性听力损失(BSNHL)的诊断至关重要,其中GJB2的致病变异是最常见的原因。目前的检测策略往往不能提供全面的诊断,通常需要使用多种检测方法。本研究评估了基因组测序(GS)在GJB2致病变异和BSNHL的杂合队列诊断中的应用价值。方法对23例BSNHL患者进行GJB2杂合致病变异的回顾性队列研究,对GJB2进行靶向重测序和变异重新解释。在单基因再分析中没有双等位基因GJB2变异体的患者使用大型虚拟听力损失相关基因面板进行外显子组测序(ES)。没有明确ES诊断的受试者随后进行GS。使用听力损失特异性ACMG指南和已发表的文献来解释变异。结果3例患者经GJB2单基因再分析诊断为双等位致病变异。ES在5/20(25%)的个体中确定了5种不同的听力损失相关基因的明确或可能的诊断,而另外2例由于另外两种听力损失相关基因的新变体或模糊变体而仍未确定。对其余15例患者进行GS分析后,3人被诊断为LOXHD1和STRC缺失,以及最近发现的125 kb重叠的cry1缺失,该缺失完善了与gjb2相关的听力损失相关的关键上游调控区域。总体而言,11/23(48%)个体通过我们的逐步检测方法得到诊断,GS提供了所有结果的测序覆盖。结论GS可捕获ES和靶向检测遗漏的snv和cnv,提高BSNHL患者的诊断率,支持将其作为非综合征性听力损失的综合一线诊断检测方法。
{"title":"Whole Genome Sequencing Improves the Identification of Pathogenic and Novel Variation in Nonsyndromic Hearing Loss","authors":"Stefan Rentas,&nbsp;Ramakrishnan Rajagopalan,&nbsp;Tolga Ayazseven,&nbsp;Mahdi Sarmady,&nbsp;Sarah E. Raible,&nbsp;Ian D. Krantz,&nbsp;Ahmad N. Abou Tayoun","doi":"10.1155/humu/6371082","DOIUrl":"https://doi.org/10.1155/humu/6371082","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Genetic testing is essential to the diagnosis of nonsyndromic bilateral sensorineural hearing loss (BSNHL), where pathogenic variants in <i>GJB2</i> are the most common cause. Current testing strategies often fail to provide a comprehensive diagnosis and typically require the use of multiple testing methodologies. This study evaluated the diagnostic utility of genome sequencing (GS) in a cohort with heterozygosity for <i>GJB2</i> pathogenic variants and BSNHL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort of 23 individuals with BSNHL and a heterozygous pathogenic variant in <i>GJB2</i> underwent targeted <i>GJB2</i> resequencing and variant reinterpretation. Those without biallelic <i>GJB2</i> variants upon single gene reanalysis proceeded to exome sequencing (ES) using a large virtual panel of hearing loss–associated genes. Subjects with no definitive diagnosis from ES subsequently underwent GS. Variants were interpreted using hearing loss–specific ACMG guidelines and published literature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three individuals were diagnosed with biallelic pathogenic variants upon <i>GJB2</i> single gene reanalysis. ES identified a definitive or likely diagnosis in five different hearing loss–related genes in 5/20 (25%) individuals, while two additional cases remained inconclusive due to novel or ambiguous variants in two other hearing loss–associated genes. GS of the remaining 15 cases yielded diagnoses in three individuals, including the identification of deletions in <i>LOXHD1</i> and <i>STRC</i>, and a recently characterized 125 kb deletion overlapping <i>CRYL1</i>, which refines a critical upstream regulatory region associated with <i>GJB2</i>-related hearing loss. Overall, 11/23 (48%) individuals received a diagnosis with our stepwise testing approach, with GS providing sequencing coverage of all findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GS improves diagnostic yield in patients with BSNHL, capturing both SNVs and CNVs missed by ES and targeted testing, and supports its adoption as a comprehensive first-tier diagnostic test for nonsyndromic hearing loss.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/6371082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights Into the Pathological Glycosylation Associated With COG6-CDG 与COG6-CDG相关的病理糖基化的见解
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-11-30 DOI: 10.1155/humu/7948771
Zuzana Pakanová, Maroš Krchňák, Marek Nemčovič, Rebeka Kodríková, Nina Ondrušková, Hana Štufková, Mária Giertlová, Katarína Okáľová, Paula Stretavská, Slavomíra Martineková, Renáta Zemjarová Mezenská, Michaela Urminská, Martina Škopková, Andrea Andrésová, Miroslava Lysinová, Lenka Belujská, Anna Šalingová, Gábor Beke, Lucia Račková, Tomáš Honzík, Hana Hansíková, Peter Baráth

Background and Aims

Congenital disorders of glycosylation (CDG) are rare diseases caused by defects in protein glycosylation. We present an infant with multisystemic clinical involvement, diagnosed with COG6-CDG.

Methods

Serum and transferrin-linked N-glycans, as well as serum and apolipoprotein CIII–linked O-glycans, were analyzed by MALDI mass spectrometry. Mutation analysis was performed by next-generation sequencing. Functional studies assessed COG6 subunit expression, cooperating subunits, and retrograde transport. GlycoWorks RapiFluor-MS–based N-glycan labeling with HPLC-FLD and ESI-Orbitrap mass spectrometry enabled further comprehensive glycoprofile analysis.

Results

Aberrant glycosylation typical of combined N- and O-glycosylation defects was detected. Mutation analysis identified a novel homozygous variant in the COG6 gene: c.906_907delinsA, p.(His302GlnfsTer4), introducing a premature stop codon and producing a truncated protein of only 304 amino acids. The diagnosis of COG6-CDG was confirmed by the complete absence of the COG6 subunit, impairment of two other cooperating subunits, and delayed retrograde transport. Independent glycoprofile analyses by HPLC-FLD and ESI-Orbitrap revealed a set of potential glycobiomarkers of COG6-CDG, including underprocessed N-glycans Hex3-5HexNAc2, Hex3-5HexNAc3, Hex3-4HexNAc4, and Hex4HexNAc3-4NeuAc1.

Conclusion

This study describes a novel COG6 variant leading to complete loss of protein function and major glycosylation abnormalities. Multiomics analysis provided deeper insights into the molecular mechanisms of this rare disease and the function of the COG6 gene and demonstrated how the mutation results in significant alterations in the patient′s (glyco)phenotype.

背景与目的先天性糖基化障碍(CDG)是由蛋白质糖基化缺陷引起的罕见疾病。我们提出一个多系统临床累及的婴儿,诊断为COG6-CDG。方法采用MALDI质谱分析血清和转铁蛋白连接的n-聚糖,血清和载脂蛋白ciii连接的o -聚糖。通过下一代测序进行突变分析。功能研究评估了COG6亚基表达、合作亚基和逆行运输。使用HPLC-FLD和ESI-Orbitrap质谱技术对基于glyworks rapifluor - ms的n -聚糖进行标记,可以进一步进行全面的糖谱分析。结果检测到典型的N-和o -糖基化结合缺陷的异常糖基化。突变分析在COG6基因中发现了一个新的纯合变异:c.906_907delinsA, p.(His302GlnfsTer4),引入了一个过早终止密码子,并产生了一个只有304个氨基酸的截断蛋白。COG6亚基完全缺失,另外两个协同亚基受损,以及延迟逆行运输,证实了COG6- cdg的诊断。通过HPLC-FLD和ESI-Orbitrap的独立糖谱分析揭示了COG6-CDG的一组潜在糖生物标志物,包括未加工的n聚糖Hex3-5HexNAc2、Hex3-5HexNAc3、Hex3-4HexNAc4和Hex4HexNAc3-4NeuAc1。本研究描述了一种新的COG6变异,导致蛋白质功能完全丧失和糖基化异常。多组学分析为这种罕见疾病的分子机制和COG6基因的功能提供了更深入的见解,并证明了突变如何导致患者(糖)表型的显著改变。
{"title":"Insights Into the Pathological Glycosylation Associated With COG6-CDG","authors":"Zuzana Pakanová,&nbsp;Maroš Krchňák,&nbsp;Marek Nemčovič,&nbsp;Rebeka Kodríková,&nbsp;Nina Ondrušková,&nbsp;Hana Štufková,&nbsp;Mária Giertlová,&nbsp;Katarína Okáľová,&nbsp;Paula Stretavská,&nbsp;Slavomíra Martineková,&nbsp;Renáta Zemjarová Mezenská,&nbsp;Michaela Urminská,&nbsp;Martina Škopková,&nbsp;Andrea Andrésová,&nbsp;Miroslava Lysinová,&nbsp;Lenka Belujská,&nbsp;Anna Šalingová,&nbsp;Gábor Beke,&nbsp;Lucia Račková,&nbsp;Tomáš Honzík,&nbsp;Hana Hansíková,&nbsp;Peter Baráth","doi":"10.1155/humu/7948771","DOIUrl":"https://doi.org/10.1155/humu/7948771","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Congenital disorders of glycosylation (CDG) are rare diseases caused by defects in protein glycosylation. We present an infant with multisystemic clinical involvement, diagnosed with COG6-CDG.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Serum and transferrin-linked N-glycans, as well as serum and apolipoprotein CIII–linked O-glycans, were analyzed by MALDI mass spectrometry. Mutation analysis was performed by next-generation sequencing. Functional studies assessed COG6 subunit expression, cooperating subunits, and retrograde transport. GlycoWorks RapiFluor-MS–based N-glycan labeling with HPLC-FLD and ESI-Orbitrap mass spectrometry enabled further comprehensive glycoprofile analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Aberrant glycosylation typical of combined N- and O-glycosylation defects was detected. Mutation analysis identified a novel homozygous variant in the <i>COG6</i> gene: c.906_907delinsA, p.(His302GlnfsTer4), introducing a premature stop codon and producing a truncated protein of only 304 amino acids. The diagnosis of COG6-CDG was confirmed by the complete absence of the COG6 subunit, impairment of two other cooperating subunits, and delayed retrograde transport. Independent glycoprofile analyses by HPLC-FLD and ESI-Orbitrap revealed a set of potential glycobiomarkers of COG6-CDG, including underprocessed N-glycans Hex3-5HexNAc2, Hex3-5HexNAc3, Hex3-4HexNAc4, and Hex4HexNAc3-4NeuAc1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study describes a novel COG6 variant leading to complete loss of protein function and major glycosylation abnormalities. Multiomics analysis provided deeper insights into the molecular mechanisms of this rare disease and the function of the <i>COG6</i> gene and demonstrated how the mutation results in significant alterations in the patient′s (glyco)phenotype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/7948771","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reclassification of VUS Using ACMG/AMP Criteria Adapted for Sarcomeric Genes Related to Hypertrophic Cardiomyopathy: Resolution Rate and Considerations 使用适用于肥厚性心肌病相关肌瘤基因的ACMG/AMP标准重新分类VUS:解决率和注意事项
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-11-29 DOI: 10.1155/humu/6500093
Silvia Caroselli, Giulia Corona, Marco Fabiani, Martina Manzoni, Caterina Micolonghi, Camilla Savio, Aldo Germani, Stefania Bragliola, Valeria Maselli, Speranza Rubattu, Beatrice Musumeci, Giacomo Tini, Vincenzo Visco, Simona Petrucci, Valeria Novelli, Maria Piane

Background

Genetic testing is valuable to confirm molecular diagnosis in nearly 60% of cases suspected of hypertrophic cardiomyopathy (HCM). However, the interpretation of variants, especially those of uncertain significance (VUSs), remains challenging for laboratories and clinicians. In April 2024, the ClinGen Cardiomyopathy Variant Curation Expert Panel (VCEP) adapted the ACMG/AMP criteria for eight of the sarcomeric genes (MYH7, MYBPC3, TNNI3, TNNT2, TPM1, ACTC1, MYL2, and MYL3), providing a refined framework for variant interpretation in these genes. This retrospective study re-evaluated 69 VUSs identified in 84 HCM patients between 2017 and 2024, aiming to resolve uncertainty and reduce the VUS rate.

Methods

Here, two groups of curators reinterpreted variants with the most recent data using the Cardiomyopathy VCEP specifications until a consensus was reached. To streamline the process, we created a semiautomated decision support tool based on these gene-specific rules.

Results

The application of the Cardiomyopathy VCEP specifications resulted in the reclassification of 17.4% (N = 12/69, 95% CI: 10.2%–28.0%) of VUS, whereas the new data alone were not sufficient. Out of the reclassified variants, 91.7% (N = 11/12) were downgraded to benignity (involving 17 patients), and 8.3% were upgraded to pathogenicity (involving one patient), with a mean reclassification time of 68.3 months, corresponding to 5.7 years. The most applied criteria were related to population (PM2 = 55%; BA1/BS1 = 16%), bioinformatic prediction (PP3 = 45%; BP4 = 25%), and critical domains (PM1 = 21%). However, most codes suffer from a lack of evidence (segregation data, functional assays, and case-control studies). When comparing this curation with classifications in public databases, 13.3% (N = 8/60) and 16.2% (N = 11/68) of variants listed as having inconclusive significance in ClinVar and CardioClassifier were, respectively, reclassified in this study.

Conclusion

Using gene-specific ACMG/AMP criteria reduces the rate of VUS, increasing diagnostic yield, and informing clinical management in the context of HCM. Nonetheless, ongoing efforts to generate evidence and promote standardization remain essential to improve variant interpretation.

基因检测对近60%的肥厚性心肌病(HCM)疑似病例的分子诊断有价值。然而,变异的解释,特别是那些不确定的意义(VUSs),仍然是实验室和临床医生的挑战。在2024年4月,ClinGen心肌病变异管理专家小组(VCEP)对8个肉瘤基因(MYH7、MYBPC3、TNNI3、TNNT2、TPM1、ACTC1、MYL2和MYL3)采用了ACMG/AMP标准,为这些基因的变异解释提供了一个完善的框架。本回顾性研究重新评估了84例HCM患者在2017年至2024年间发现的69例VUS,旨在消除不确定性并降低VUS发生率。方法在这里,两组管理员使用心肌病VCEP规范重新解释变异的最新数据,直到达成共识。为了简化这个过程,我们基于这些特定基因的规则创建了一个半自动的决策支持工具。结果应用心肌病VCEP规范导致17.4%的VUS重新分类(N = 12/69, 95% CI: 10.2% ~ 28.0%),而单独使用新数据是不够的。在重分类变异中,91.7% (N = 11/12)降为良性(涉及17例患者),8.3%升级为致病性(涉及1例患者),平均重分类时间为68.3个月,相当于5.7年。应用最多的标准与种群(PM2 = 55%; BA1/BS1 = 16%)、生物信息学预测(PP3 = 45%; BP4 = 25%)和关键域(PM1 = 21%)相关。然而,大多数代码都缺乏证据(分离数据、功能分析和病例对照研究)。当与公共数据库的分类进行比较时,本研究中分别有13.3% (N = 8/60)和16.2% (N = 11/68)在ClinVar和CardioClassifier中被列为无决定性意义的变异被重新分类。结论采用基因特异性ACMG/AMP标准可降低VUS发生率,提高诊断率,为HCM的临床管理提供依据。尽管如此,正在进行的产生证据和促进标准化的努力仍然是改进变异解释的必要条件。
{"title":"Reclassification of VUS Using ACMG/AMP Criteria Adapted for Sarcomeric Genes Related to Hypertrophic Cardiomyopathy: Resolution Rate and Considerations","authors":"Silvia Caroselli,&nbsp;Giulia Corona,&nbsp;Marco Fabiani,&nbsp;Martina Manzoni,&nbsp;Caterina Micolonghi,&nbsp;Camilla Savio,&nbsp;Aldo Germani,&nbsp;Stefania Bragliola,&nbsp;Valeria Maselli,&nbsp;Speranza Rubattu,&nbsp;Beatrice Musumeci,&nbsp;Giacomo Tini,&nbsp;Vincenzo Visco,&nbsp;Simona Petrucci,&nbsp;Valeria Novelli,&nbsp;Maria Piane","doi":"10.1155/humu/6500093","DOIUrl":"https://doi.org/10.1155/humu/6500093","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Genetic testing is valuable to confirm molecular diagnosis in nearly 60% of cases suspected of hypertrophic cardiomyopathy (HCM). However, the interpretation of variants, especially those of uncertain significance (VUSs), remains challenging for laboratories and clinicians. In April 2024, the ClinGen Cardiomyopathy Variant Curation Expert Panel (VCEP) adapted the ACMG/AMP criteria for eight of the sarcomeric genes (<i>MYH7</i>, <i>MYBPC3</i>, <i>TNNI3</i>, <i>TNNT2</i>, <i>TPM1</i>, <i>ACTC1</i>, <i>MYL2</i>, and <i>MYL3</i>), providing a refined framework for variant interpretation in these genes. This retrospective study re-evaluated 69 VUSs identified in 84 HCM patients between 2017 and 2024, aiming to resolve uncertainty and reduce the VUS rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Here, two groups of curators reinterpreted variants with the most recent data using the Cardiomyopathy VCEP specifications until a consensus was reached. To streamline the process, we created a semiautomated decision support tool based on these gene-specific rules.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The application of the Cardiomyopathy VCEP specifications resulted in the reclassification of 17.4% (<i>N</i> = 12/69, 95% CI: 10.2%–28.0%) of VUS, whereas the new data alone were not sufficient. Out of the reclassified variants, 91.7% (<i>N</i> = 11/12) were downgraded to benignity (involving 17 patients), and 8.3% were upgraded to pathogenicity (involving one patient), with a mean reclassification time of 68.3 months, corresponding to 5.7 years. The most applied criteria were related to population (PM2 = 55<i>%</i>; BA1/BS1 = 16<i>%</i>), bioinformatic prediction (PP3 = 45<i>%</i>; BP4 = 25<i>%</i>), and critical domains (PM1 = 21<i>%</i>). However, most codes suffer from a lack of evidence (segregation data, functional assays, and case-control studies). When comparing this curation with classifications in public databases, 13.3% (<i>N</i> = 8/60) and 16.2% (<i>N</i> = 11/68) of variants listed as having inconclusive significance in ClinVar and CardioClassifier were, respectively, reclassified in this study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Using gene-specific ACMG/AMP criteria reduces the rate of VUS, increasing diagnostic yield, and informing clinical management in the context of HCM. Nonetheless, ongoing efforts to generate evidence and promote standardization remain essential to improve variant interpretation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/6500093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145619348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated Genomic and Functional Characterization of Palmitoylation in Clear Cell Renal Cell Carcinoma 透明细胞肾细胞癌中棕榈酰化的整合基因组和功能表征
IF 3.7 2区 医学 Q2 GENETICS & HEREDITY Pub Date : 2025-11-29 DOI: 10.1155/humu/4647115
Dong Zhang, Ke Zhang, Minghao Deng, Jiakang Ma, Jian Zhu, Shuijie Shen, Jianjun Xie, Chao Chen

Background

Clear cell renal cell carcinoma (ccRCC) is a highly aggressive cancer with a poor prognosis. Palmitoylation, a posttranslational modification, plays a key role in regulating cancer progression and immune responses. However, its influence on ccRCC prognosis and immune therapy efficacy remains underexplored.

Methods

Multiple publicly available ccRCC datasets were integrated and harmonized through batch effect correction. A prognostic model based on palmitoylation-related genes was constructed using a combination of 101 machine learning algorithms. Single-cell RNA sequencing was employed to analyze cellular heterogeneity within the tumor microenvironment. Genomic profiling, including tumor mutational burden (TMB), copy number variation (CNV), and tumor stemness, was conducted to identify genomic differences between the high- and low-risk groups. Immune infiltration levels were assessed using various algorithms to compare immune profiles across patient subgroups, while immune therapy responses were predicted using multiple prediction models. Experimental validation of ZDHHC18, a key gene in the prognostic model, was performed in ccRCC cell lines (786-O and Caki-1) to evaluate its impact on cell proliferation, migration, and invasion.

Results

The palmitoylation-related prognostic model effectively stratified ccRCC patients into the high- and low-risk groups, with distinct differences in survival outcomes. Genomic analysis demonstrated higher TMB and CNV alterations in the high-risk group. Immune response predictions indicated that low-risk patients were more likely to benefit from immunotherapy. Additionally, ZDHHC18 was significantly upregulated in ccRCC tumor tissues, and its knockdown notably inhibited cell proliferation, migration, and invasion.

Conclusion

Palmitoylation-related genes, particularly ZDHHC18, serve as promising prognostic biomarkers and predictive indicators for immune therapy in ccRCC. These findings offer new insights into ccRCC biology and highlight potential therapeutic targets for improving patient outcomes.

透明细胞肾细胞癌(ccRCC)是一种侵袭性强、预后差的肿瘤。棕榈酰化是一种翻译后修饰,在调节癌症进展和免疫反应中起着关键作用。然而,其对ccRCC预后和免疫治疗效果的影响尚不清楚。方法通过批量效应校正对多个公开的ccRCC数据集进行整合和协调。结合101种机器学习算法构建了基于棕榈酰化相关基因的预后模型。单细胞RNA测序用于分析肿瘤微环境中的细胞异质性。基因组分析包括肿瘤突变负担(TMB)、拷贝数变异(CNV)和肿瘤干性,以确定高风险组和低风险组之间的基因组差异。使用各种算法评估免疫浸润水平,以比较患者亚组的免疫概况,同时使用多种预测模型预测免疫治疗反应。我们在ccRCC细胞系(786-O和Caki-1)中对预后模型中的关键基因ZDHHC18进行了实验验证,以评估其对细胞增殖、迁移和侵袭的影响。结果棕榈酰化相关预后模型有效地将ccRCC患者分为高危组和低危组,生存结果有明显差异。基因组分析显示,高危组的TMB和CNV变化较高。免疫反应预测表明,低风险患者更有可能从免疫治疗中获益。此外,ZDHHC18在ccRCC肿瘤组织中显著上调,其下调显著抑制细胞增殖、迁移和侵袭。结论棕榈酰化相关基因,尤其是ZDHHC18,可作为ccRCC免疫治疗的预后生物标志物和预测指标。这些发现为ccRCC生物学提供了新的见解,并突出了改善患者预后的潜在治疗靶点。
{"title":"Integrated Genomic and Functional Characterization of Palmitoylation in Clear Cell Renal Cell Carcinoma","authors":"Dong Zhang,&nbsp;Ke Zhang,&nbsp;Minghao Deng,&nbsp;Jiakang Ma,&nbsp;Jian Zhu,&nbsp;Shuijie Shen,&nbsp;Jianjun Xie,&nbsp;Chao Chen","doi":"10.1155/humu/4647115","DOIUrl":"https://doi.org/10.1155/humu/4647115","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Clear cell renal cell carcinoma (ccRCC) is a highly aggressive cancer with a poor prognosis. Palmitoylation, a posttranslational modification, plays a key role in regulating cancer progression and immune responses. However, its influence on ccRCC prognosis and immune therapy efficacy remains underexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Multiple publicly available ccRCC datasets were integrated and harmonized through batch effect correction. A prognostic model based on palmitoylation-related genes was constructed using a combination of 101 machine learning algorithms. Single-cell RNA sequencing was employed to analyze cellular heterogeneity within the tumor microenvironment. Genomic profiling, including tumor mutational burden (TMB), copy number variation (CNV), and tumor stemness, was conducted to identify genomic differences between the high- and low-risk groups. Immune infiltration levels were assessed using various algorithms to compare immune profiles across patient subgroups, while immune therapy responses were predicted using multiple prediction models. Experimental validation of ZDHHC18, a key gene in the prognostic model, was performed in ccRCC cell lines (786-O and Caki-1) to evaluate its impact on cell proliferation, migration, and invasion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The palmitoylation-related prognostic model effectively stratified ccRCC patients into the high- and low-risk groups, with distinct differences in survival outcomes. Genomic analysis demonstrated higher TMB and CNV alterations in the high-risk group. Immune response predictions indicated that low-risk patients were more likely to benefit from immunotherapy. Additionally, ZDHHC18 was significantly upregulated in ccRCC tumor tissues, and its knockdown notably inhibited cell proliferation, migration, and invasion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Palmitoylation-related genes, particularly ZDHHC18, serve as promising prognostic biomarkers and predictive indicators for immune therapy in ccRCC. These findings offer new insights into ccRCC biology and highlight potential therapeutic targets for improving patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13061,"journal":{"name":"Human Mutation","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/humu/4647115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145619349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Mutation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1